Gsk (GSK) Liabilities and Shareholders Equity (2009 - 2026)

Gsk (GSK) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $82.8 billion in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 4.78% year-over-year to $82.8 billion; the trailing twelve-month figure through Jun 2026 stood at $331.7 billion (up 7.94% YoY), and the FY2025 full-year result was $81.3 billion, up 6.96% from the prior year.
• Liabilities and Shareholders Equity was $82.8 billion for Q2 2026 at Gsk, down from $84.8 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $112.1 billion in Q2 2022 to a low of $60.4 billion in Q1 2022.
• A 5-year average of $77.6 billion and a median of $75.9 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity slumped 43.89% in 2022 and advanced 17.89% in 2023, its largest moves.
• Gsk's Liabilities and Shareholders Equity stood at $70.5 billion in 2022, then gained by 3.81% to $73.2 billion in 2023, then grew by 4.21% to $76.3 billion in 2024, then advanced by 6.52% to $81.3 billion in 2025, then gained by 1.89% to $82.8 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $82.8 billion in Q2 2026, $84.8 billion in Q1 2026, and $81.3 billion in Q4 2025.